Switching treatments in haemophilia: is there a risk of inhibitor development?

Switching treatments in haemophilia: is there a risk of inhibitor development?

Patients with haemophilia A (and their physicians) may be reluctant to switch factor VIII (FVIII) concentrates, often due to concerns about increasing the risk of inhibitors; this reluctance to switch may contribute to patients missing the clinical benefits provided by the arrival of new factor VIII...

Full description

Bibliographic Details
Main Authors: Santagostino, Elena, Auerswald, Günter, Benson, Gary, Dolan, Gerry, Jiménez-Yuste, Victor, Lambert, Thierry, Ljung, Rolf, Morfini, Massimo, Remor, Eduardo, Zupančić Šalek, Silva
Format: Online
Language:English
Published: BlackWell Publishing Ltd 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407931/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407931/

Similar Items